Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model.
inflammatory bowel diseases
infliximab
pharmacokinetics
target-mediated drug disposition
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
01 Nov 2021
01 Nov 2021
Historique:
received:
14
09
2021
revised:
18
10
2021
accepted:
19
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Infliximab is an anti-TNF-α monoclonal antibody approved in chronic inflammatory bowel diseases (IBD). This study aimed at providing an in-depth description of infliximab target-mediated pharmacokinetics in 133 IBD patients treated with 5 mg/kg infliximab at weeks 0, 2, 14, and 22. A two-compartment model with double target-mediated drug disposition (TMDD) in both central and peripheral compartments was developed, using a rich database of 26 ankylosing spondylitis patients as a reference for linear elimination kinetics. Population approach and quasi-steady-state (QSS) approximation were used. Concentration-time data were satisfactorily described using the double-TMDD model. Target-mediated parameters of central and peripheral compartments were respectively baseline TNF concentrations (R
Identifiants
pubmed: 34834236
pii: pharmaceutics13111821
doi: 10.3390/pharmaceutics13111821
pmc: PMC8623740
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pharmacol Ther. 2016 Mar;159:110-9
pubmed: 26808166
MAbs. 2017 May/Jun;9(4):680-695
pubmed: 28323513
Clin Exp Immunol. 1990 Aug;81(2):301-5
pubmed: 2117510
Protein Sci. 2017 Dec;26(12):2392-2398
pubmed: 28940886
J Biol Chem. 1986 Nov 15;261(32):14871-4
pubmed: 3021754
Ther Drug Monit. 2006 Apr;28(2):169-74
pubmed: 16628126
Biochem J. 1992 Jun 15;284 ( Pt 3):905-10
pubmed: 1622406
J Immunol. 1985 Dec;135(6):3972-7
pubmed: 2999236
J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):429-51
pubmed: 22851162
Rheumatol Int. 2012 Jan;32(1):145-50
pubmed: 20680285
Arzneimittelforschung. 1989 Sep;39(9):1180-2
pubmed: 2590273
J Pharmacokinet Pharmacodyn. 2001 Dec;28(6):507-32
pubmed: 11999290
Gut. 1991 Aug;32(8):913-7
pubmed: 1885073
Eur J Clin Pharmacol. 2015 Dec;71(12):1541-2
pubmed: 26369535
Drug Metab Pharmacokinet. 2007 Feb 25;22(1):20-5
pubmed: 17329907
Sci Rep. 2020 Jun 9;10(1):9265
pubmed: 32518229
Clin Pharmacokinet. 2021 Aug 5;:
pubmed: 34351609
MAbs. 2017 Jan;9(1):15-28
pubmed: 27661132
Clin Pharmacokinet. 2019 Feb;58(2):169-187
pubmed: 29802542
Cancer Chemother Pharmacol. 1987;20(2):137-44
pubmed: 3664933
Clin Immunol. 2009 May;131(2):308-16
pubmed: 19188093
Drug Metab Pharmacokinet. 2014;29(3):272-7
pubmed: 24418824
Biomed Res Int. 2014;2014:675108
pubmed: 24783218
Clin Pharmacol Ther. 2021 Jun;109(6):1639-1647
pubmed: 33354765
Clin Pharmacokinet. 2018 Sep;57(9):1173-1184
pubmed: 29236229
Int J Mol Sci. 2018 Mar 07;19(3):
pubmed: 29518978
CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):324-37
pubmed: 26225261
Sci Rep. 2016 Sep 08;6:32747
pubmed: 27605058
Ther Drug Monit. 2008 Aug;30(4):523-9
pubmed: 18641542
Br J Clin Pharmacol. 2012 Jan;73(1):55-65
pubmed: 21692827
J Clin Pharmacol. 2018 Jun;58(6):790-802
pubmed: 29381220
Pharmaceutics. 2021 Aug 03;13(8):
pubmed: 34452152
J Mol Biol. 2007 Dec 14;374(5):1374-88
pubmed: 17996896
Scand J Gastroenterol. 2020 Aug;55(8):884-890
pubmed: 32631131
Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):803-12
pubmed: 19505189
J Pharmacol Exp Ther. 2002 May;301(2):418-26
pubmed: 11961039
Clin Pharmacokinet. 2020 Jul;59(7):857-874
pubmed: 32170579
MAbs. 2016 Oct;8(7):1407-1416
pubmed: 27589009
Br J Clin Pharmacol. 2021 Mar;87(3):1594-1595
pubmed: 33269471
J Pharmacol Exp Ther. 1989 Oct;251(1):358-61
pubmed: 2795465
Ther Drug Monit. 2017 Aug;39(4):339-343
pubmed: 28486309
Biopharm Drug Dispos. 2019 Jul;40(7):250-261
pubmed: 31256430
J Pharmacokinet Pharmacodyn. 2019 Dec;46(6):543-551
pubmed: 31489538